62 results on '"Leise MD"'
Search Results
2. 75-year-old man with abdominal pain and weight loss.
- Author
-
Leise MD, Jacobson KM, and Chari ST
- Published
- 2008
3. Changing Landscape of Liver Transplantation in the Post-DAA and Contemporary ART Era.
- Author
-
Saeed H, Cano EJ, Khan MQ, Yetmar ZA, Smith B, Rizza SA, Badley AD, Mahmood M, Leise MD, and Cummins NW
- Abstract
Combination anti-retroviral therapy has drastically improved solid organ transplantation outcomes in persons living with HIV. DAA therapy has led to the successful eradication of HCV. While recent data have suggested improvement in outcomes in HIV/HCV-coinfected liver transplant recipients, temporal trends in patient survival within pre- and post-DAA eras are yet to be elucidated. The UNOS database was utilized to identify deceased donor liver transplant recipients between 1 January 2000 and 30 September 2020 and stratify them by HIV and HCV infection status. A total of 85,730 patients met the inclusion criteria. One-year and five-year patient survival improved (93% and 80%, respectively) for all transplants performed post-2015. For HIV/HCV-coinfected recipients, survival improved significantly from 78% (pre-2015) to 92% (post-2015). Multivariate regression analyses identified advanced recipient age, Black race, diabetes mellitus and decompensated cirrhosis as risk factors associated with higher one-year mortality. Liver transplant outcomes in HIV/HCV-coinfected liver transplant recipients have significantly improved over the last quinquennium in the setting of the highly effective combination of ART and DAA therapy. The presence of HIV, HCV, HIV/HCV-coinfection and active HCV viremia at the time of transplant do not cause higher mortality risk in liver transplant recipients in the current era.
- Published
- 2022
- Full Text
- View/download PDF
4. Diffuse Common Bile Duct Mural Thickening in a Patient With Pancreatitis.
- Author
-
Aseem SO, Leise MD, and Law RJ
- Subjects
- Common Bile Duct diagnostic imaging, Diagnosis, Differential, Humans, Autoimmune Diseases diagnosis, Cholangitis, Sclerosing diagnosis, Pancreatitis complications, Pancreatitis diagnostic imaging
- Published
- 2022
- Full Text
- View/download PDF
5. Pseudo-Wilsonian Crisis in a ATP7B Heterozygote.
- Author
-
Khan MQ, Chin JY, Azhari H, Rosen CB, and Leise MD
- Subjects
- Copper metabolism, Copper-Transporting ATPases genetics, Female, Heterozygote, Humans, Middle Aged, Hepatolenticular Degeneration, Liver Transplantation
- Published
- 2022
- Full Text
- View/download PDF
6. Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient.
- Author
-
Yohanathan L, Campioli CC, Mousa OY, Watt K, Friedman DZP, Shah V, Ramkissoon R, Hines AS, Kamath PS, Razonable RR, Badley AD, DeMartino ES, Joyner MJ, Graham R, Vergidis P, Simonetto DA, Sanchez W, Taner T, Heimbach JK, Beam E, and Leise MD
- Subjects
- Adolescent, Female, Humans, Pandemics, Polymerase Chain Reaction, SARS-CoV-2, COVID-19, Liver Failure, Acute etiology, Liver Failure, Acute surgery, Liver Transplantation adverse effects
- Abstract
Current guidelines recommend deferring liver transplantation (LT) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection until clinical improvement occurs and two PCR tests collected at least 24 hours apart are negative. We report a case of an 18-year-old, previously healthy African-American woman diagnosed with COVID-19, who presents with acute liver failure (ALF) requiring urgent LT in the context of SARS-CoV-2 polymerase chain reaction (PCR) positivity. The patient was thought to have acute Wilsonian crisis on the basis of hemolytic anemia, alkaline phosphatase:bilirubin ratio <4, AST:ALT ratio >2.2, elevated serum copper, and low uric acid, although an unusual presentation of COVID-19 causing ALF could not be excluded. After meeting criteria for status 1a listing, the patient underwent successful LT, despite ongoing SARS-CoV-2 PCR positivity. Remdesivir was given immediately posttransplant, and mycophenolate mofetil was withheld initially and the SARS-CoV-2 PCR test eventually became negative. Three months following transplantation, the patient has made a near-complete recovery. This case highlights that COVID-19 with SARS-CoV-2 PCR positivity may not be an absolute contraindication for transplantation in ALF. Criteria for patient selection and timing of LT amid the COVID-19 pandemic need to be validated in future studies., (© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2021
- Full Text
- View/download PDF
7. Incidence and predictors of 30-day hospital readmissions for liver cirrhosis: insights from the United States National Readmissions Database.
- Author
-
Garg SK, Goyal H, Obaitan I, Shah PA, Sarvepalli S, Jophlin LL, Singh D, Asrani S, Kamath PS, and Leise MD
- Abstract
Background: Cirrhosis is associated with substantial inpatient morbidity and mortality. This study aimed to determine the trends in 30-day hospital readmission rates among patients with cirrhosis and identify factors associated with these readmissions., Methods: We conducted a retrospective analysis of data retrieved from the Nationwide Readmissions Database to determine trends in 30-day readmission for patients discharged with a diagnosis of cirrhosis in 2010 through 2014. Multivariate logistic regression analysis was used to identify predictors of readmission., Results: Among 303,346 patients identified from the database, the 30-day readmission rate for patients with a discharge diagnosis of cirrhosis was 31.4% (n=95,298). The trends in the readmission rates remained steady during the study period. On multivariate analysis, female sex, age 45 years or older, esophagogastroduodenoscopy (EGD) during admission, and disposition to a short-term care facility or skilled nursing facility protected against readmissions. In contrast, coverage by Medicaid insurance, admission during a weekend, nonalcoholic cause of cirrhosis, and history of hepatic encephalopathy and ascites were associated with readmission., Conclusions: We found an exceptionally high 30-day readmission rate in patients with cirrhosis, although it remained stable during the study period. This study identified some modifiable factors such as disposition to a short-term care facility or skilled nursing facility and patients' attendance of alcohol rehabilitation facilities that could decrease the likelihood of readmission and could inform local and national healthcare policymakers., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/atm-20-1762). The authors have no conflicts of interest to declare., (2021 Annals of Translational Medicine. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: A systematic review and meta-analysis of autopsy data.
- Author
-
Díaz LA, Idalsoaga F, Cannistra M, Candia R, Cabrera D, Barrera F, Soza A, Graham R, Riquelme A, Arrese M, Leise MD, and Arab JP
- Subjects
- COVID-19 diagnosis, COVID-19 mortality, COVID-19 virology, Fatty Liver etiology, Fatty Liver pathology, Humans, Kupffer Cells pathology, Liver blood supply, Liver cytology, Prevalence, SARS-CoV-2 isolation & purification, SARS-CoV-2 pathogenicity, Venous Thrombosis etiology, Venous Thrombosis pathology, COVID-19 complications, Fatty Liver epidemiology, Hepatic Veins pathology, Liver pathology, Venous Thrombosis epidemiology
- Abstract
Background: Coronavirus disease 2019 (COVID-19) disease can frequently affect the liver. Data on hepatic histopathological findings in COVID-19 is scarce., Aim: To characterize hepatic pathological findings in patients with COVID-19., Methods: We conducted a systematic review with meta-analysis registered on PROSPERO (CRD42020192813), following PRISMA guidelines. Eligible trials were those including patients of any age and COVID-19 diagnosis based on a molecular test. Histopathological reports from deceased COVID-19 patients undergoing autopsy or liver biopsy were reviewed. Articles including less than ten patients were excluded. Proportions were pooled using random-effects models. Q statistic and I
2 were used to assess heterogeneity and levels of evidence, respectively., Results: We identified 18 studies from 7 countries; all were case reports and case series from autopsies. All the patients were over 15 years old, and 67.2% were male. We performed a meta-analysis of 5 studies, including 116 patients. Pooled prevalence estimates of liver histopathological findings were hepatic steatosis 55.1% [95% confidence interval (CI): 46.2-63.8], congestion of hepatic sinuses 34.7% (95%CI: 7.9-68.4), vascular thrombosis 29.4% (95%CI: 0.4-87.2), fibrosis 20.5% (95%CI: 0.6-57.9), Kupffer cell hyperplasia 13.5% (95%CI: 0.6-54.3), portal inflammation 13.2% (95%CI: 0.1-48.8), and lobular inflammation 11.6% (95%CI: 0.3-35.7). We also identified the presence of venous outflow obstruction, phlebosclerosis of the portal vein, herniated portal vein, periportal abnormal vessels, hemophagocytosis, and necrosis., Conclusion: We found a high prevalence of hepatic steatosis and vascular thrombosis as major histological liver features. Other frequent findings included portal and lobular inflammation and Kupffer cell hyperplasia or proliferation. Further studies are needed to establish the mechanisms and implications of these findings., Competing Interests: Conflict-of-interest statement: The authors have nothing to disclose., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
9. Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C.
- Author
-
Tse CS, Yang JD, Mousa OY, Nelson KM, Pungpapong S, Keaveny A, Aqel BA, Vargas H, Dickson RC, Watt K, Gores GJ, Roberts LR, and Leise MD
- Abstract
Direct-acting antivirals (DAA) are highly effective for the treatment of hepatitis C (HCV), although there are limited data on the safety and efficacy of DAA therapy in hepatitis C-positive individuals awaiting liver transplantation for hepatocellular carcinoma (HCC)., Methods: We conducted a retrospective cohort study of HCV-positive patients who underwent liver transplantation for HCC at 3 liver transplant centers across the United States from 2014 to 2017 with follow-up to July 2018. Transplant recipients who received DAA before transplant were compared with those who did not (DAA naive) for posttransplant HCC recurrence rate, sustained virological response (SVR), allograft failure, and death using Kaplan-Meier analysis and Cox proportional hazard models., Results: A total of 171 HCV-HCC transplant recipients (99 pretransplant DAA; 72 DAA naive controls) were included, with a median follow-up of 24 months. The overall posttransplant HCC recurrence rate was 9% (15/171). Pretransplant DAA was not associated with HCC recurrence (5% versus 14%; P = 0.07), graft failure (7% versus 3%; P = 0.21), or death (12% versus 19%; P = 0.19) as compared with DAA naive patients. SVR rates were significantly lower ( P < 0.01) with pretransplant DAA (75%, 39/52) than posttransplant DAA (97%, 59/61) therapies. Those who received pretransplant DAA and those who did not were not statistically different in age, gender, alpha fetal protein levels, model for end-stage liver disease scores, or transplant wait time., Conclusions: Pretransplant DAA for HCV was not associated with an increased risk of posttransplant HCC recurrence, though pretransplant DAA had lower efficacy than posttransplant DAA in HCV-HCC transplant recipients., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.)
- Published
- 2020
- Full Text
- View/download PDF
10. Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease.
- Author
-
Sarmast N, Ogola GO, Kouznetsova M, Leise MD, Bahirwani R, Maiwall R, Tapper E, Trotter J, Bajaj JS, Thacker LR, Tandon P, Wong F, Reddy KR, O'Leary JG, Masica A, Modrykamien AM, Kamath PS, and Asrani SK
- Subjects
- Aged, Clinical Decision-Making, Decision Support Techniques, End Stage Liver Disease blood, End Stage Liver Disease diagnosis, End Stage Liver Disease therapy, Female, Humans, Liver Cirrhosis blood, Liver Cirrhosis diagnosis, Liver Cirrhosis therapy, Male, Middle Aged, Nomograms, Patient Admission statistics & numerical data, Prospective Studies, Risk Assessment methods, Risk Assessment statistics & numerical data, End Stage Liver Disease mortality, Hospital Mortality, Lactic Acid blood, Liver Cirrhosis mortality, Severity of Illness Index
- Abstract
Background and Aims: Compared to other chronic diseases, patients with chronic liver disease (CLD) have significantly higher inpatient mortality; accurate models to predict inpatient mortality are lacking. Serum lactate (LA) may be elevated in patients with CLD due to both tissue hypoperfusion as well as decreased LA clearance. We hypothesized that a parsimonious model consisting of Model for End-Stage Liver Disease (MELD) and LA at admission may predict inpatient mortality in patients with CLD., Approach and Results: We examined all patients with CLD in two large and diverse health care systems in Texas (North Texas [NTX] and Central Texas [CTX]) between 2010 and 2015. We developed (n = 3,588) and validated (n = 1,804) a model containing MELD and LA measured at the time of hospitalization. We further validated the model in a second cohort of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 726). MELD-LA was an excellent predictor of inpatient mortality in development (concordance statistic [C-statistic] = 0.81, 95% confidence interval [CI] 0.79-0.82) and both validation cohorts (CTX cohort, C-statistic = 0.85, 95% CI 0.78-0.87; multicenter cohort C-statistic = 0.82, 95% CI 0.74-0.88). MELD-LA performed especially well in patients with specific cirrhosis diagnoses (C-statistic = 0.84, 95% CI 0.81-0.86) or sepsis (C-statistic = 0.80, 95% CI 0.78-0.82). For MELD score 25, inpatient mortality rates were 11.2% (LA = 1 mmol/L), 19.4% (LA = 3 mmol/L), 34.3% (LA = 5 mmol/L), and >50% (LA > 8 mmol/L). A linear increase (P < 0.01) was seen in MELD-LA and increasing number of organ failures. Overall, use of MELD-LA improved the risk prediction in 23.5% of patients compared to MELD alone., Conclusions: MELD-LA (bswh.md/meldla) is an early and objective predictor of inpatient mortality and may serve as a model for risk assessment and guide therapeutic options., (© 2020 by the American Association for the Study of Liver Diseases.)
- Published
- 2020
- Full Text
- View/download PDF
11. The Current Hepatic Encephalopathy Pipeline.
- Author
-
Ryu AJ, Rahimi RS, and Leise MD
- Abstract
Hepatic encephalopathy (HE) is a complication of acute or chronic liver failure; its mechanism is complex, involving multiple organ systems, and is still being elucidated. The standard of care, lactulose, has remained generally unchanged for decades. However, in recent years, better understanding of the pathophysiology has yielded new therapeutic targets for this reversible condition. These novel treatments act both on traditional pathways established in the ammonia hypothesis and through more recently discovered mechanisms. Here, we review contemporary investigational therapies for HE. We used narrative reviews and searched ClinicalTrials.gov database for the condition "hepatic encephalopathy" through August 29, 2019. Our review yielded six key areas of therapeutic focus: (1) antibiotics against urease-producing gut bacteria, (2) intravenous ammonia scavengers, (3) modified synthetic probiotics, (4) fecal microbiota transplant, (5) brain steroid-modulating agents, and 6) nonlactulose laxatives. Active trials are ongoing in each of these therapeutic areas., Competing Interests: R.S.R. served on advisory boards for Mallinckrodt and has received research support from Valeant and Mallinckrodt (formerly Ocera Therapeutics). M.L.D. and A.J.R. have nothing to disclose., (© 2020 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
12. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List.
- Author
-
Asrani SK, Jennings LW, Kim WR, Kamath PS, Levitsky J, Nadim MK, Testa G, Leise MD, Trotter JF, and Klintmalm G
- Subjects
- Adult, Aged, Creatinine blood, Female, Humans, Male, Middle Aged, Models, Theoretical, Sodium blood, Glomerular Filtration Rate, Liver Cirrhosis mortality, Liver Transplantation, Waiting Lists mortality
- Abstract
Background and Aims: Among patients with cirrhosis awaiting liver transplantation, prediction of wait-list (WL) mortality is adjudicated by the Model for End Stage Liver Disease-Sodium (MELD-Na) score. Replacing serum creatinine (SCr) with estimated glomerular filtration rate (eGFR) in the MELD-Na score may improve prediction of WL mortality, especially for women and highest disease severity., Approach and Results: We developed (2014) and validated (2015) a model incorporating eGFR using national data (n = 17,095) to predict WL mortality. Glomerular filtration rate (GFR) was estimated using the GFR assessment in liver disease (GRAIL) developed among patients with cirrhosis. Multivariate Cox proportional hazard analysis models were used to compare the predicted 90-day WL mortality between MELD-GRAIL-Na (re-estimated bilirubin, international normalized ratio [INR], sodium, and GRAIL) versus MELD-Na. Within 3 months, 27.8% were transplanted, 4.3% died on the WL, and 4.7% were delisted for other reasons. GFR as estimated by GRAIL (hazard ratio [HR] 0.382, 95% confidence interval [CI] 0.344-0.424) and the re-estimated model MELD-GRAIL-Na (HR 1.212, 95% CI 1.199-1.224) were significant predictors of mortality or being delisted on the WL within 3 months. MELD-GRAIL-Na was a better predictor of observed mortality at highest deciles of disease severity (≥ 27-40). For a score of 32 or higher (observed mortality 0.68), predicted mortality was 0.67 (MELD-GRAIL-Na) and 0.51 (MELD-Na). For women, a score of 32 or higher (observed mortality 0.67), the predicted mortality was 0.69 (MELD-GRAIL-Na) and 0.55 (MELD-Na). In 2015, use of MELD-GRAIL-Na as compared with MELD-Na resulted in reclassification of 16.7% (n = 672) of patients on the WL., Conclusion: Incorporation of eGFR likely captures true GFR better than SCr, especially among women. Incorporation of MELD-GRAIL-Na instead of MELD-Na may affect outcomes for 12%-17% awaiting transplant and affect organ allocation., (© 2019 by the American Association for the Study of Liver Diseases.)
- Published
- 2020
- Full Text
- View/download PDF
13. Incidence and Risk Factors Associated With 30-Day Readmission for Alcoholic Hepatitis.
- Author
-
Garg SK, Sarvepalli S, Singh D, Obaitan I, Peeraphatdit T, Jophlin L, Asrani SK, Shah VH, and Leise MD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Databases, Factual, Female, Humans, Incidence, Male, Middle Aged, Risk Factors, United States, Young Adult, Hepatitis, Alcoholic, Patient Readmission statistics & numerical data
- Abstract
Background: Alcohol abuse and liver disease are associated with high rates of 30-day hospital readmission, but factors linking alcoholic hepatitis (AH) to readmission are not well understood. We aimed to determine the incidence rate of 30-day readmission for patients with AH and to evaluate potential predictors of readmission., Methods: We used the Nationwide Readmissions Database to determine the 30-day readmission rate for recurrent AH between 2010 and 2014 and examined trends in readmissions during the study period. We also identified the 20 most frequent reasons for readmission. Multivariate survey logistic regression analysis was used to identify factors associated with 30-day readmission., Results: Of the 61,750 index admissions for AH, 23.9% were readmitted within 30-days. The rate of readmission did not change significantly during the study period. AH, alcoholic cirrhosis, and hepatic encephalopathy were the most frequent reasons for readmission. In multivariate analysis female sex, leaving against medical advice, higher Charlson comorbidity index, ascites, and history of bariatric surgery were associated with earlier readmissions, whereas older age, payer type (private or self-pay/other), and discharge to skilled nursing-facility reduced this risk., Conclusions: The 30-day readmission rate in patients with AH was high and stable during the study period. Factors associated with readmission may be helpful for development of consensus-based expert guidelines, treatment algorithms, and policy changes to help decrease readmission in AH.
- Published
- 2019
- Full Text
- View/download PDF
14. Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States.
- Author
-
Iyer VN, Saberi B, Heimbach JK, Larson JJ, Raghavaiah S, Ditah I, Swanson K, Kamath PS, Watt KD, Taner T, Krowka MJ, and Leise MD
- Subjects
- Adult, Aged, Cardiac Output, High epidemiology, Cardiac Output, High physiopathology, Databases, Factual, Female, Graft Survival, Heart Failure epidemiology, Heart Failure physiopathology, Humans, Liver Failure diagnosis, Liver Failure mortality, Liver Failure physiopathology, Liver Transplantation adverse effects, Liver Transplantation mortality, Male, Middle Aged, Recovery of Function, Registries, Retrospective Studies, Telangiectasia, Hereditary Hemorrhagic diagnosis, Telangiectasia, Hereditary Hemorrhagic mortality, Telangiectasia, Hereditary Hemorrhagic physiopathology, Time Factors, Treatment Outcome, United States epidemiology, Ventricular Function, Left, Liver Failure surgery, Liver Transplantation trends, Outcome and Process Assessment, Health Care trends, Telangiectasia, Hereditary Hemorrhagic surgery
- Abstract
Background: Liver arteriovenous malformations (AVM) in hereditary hemorrhagic telangiectasia (HHT) can necessitate liver transplantation. There is limited data on HHT patients undergoing liver transplantation (LT) in the United States., Methods: Two sources of data were used: (1) Scientific Registry of Transplant Recipients (SRTR) database (1998-2016) (2) Single center liver transplant database (Mayo Clinic Rochester, MN). The aims of this study were (1) to determine trends in LT for HHT-related liver involvement in the United States using the SRTR database; (2) to identify clinical characteristics, indications, and outcomes for LT in HHT., Results: Thirty-nine HHT patients were listed for LT in the SRTR database from 1998-2016 to 1998-2001 (n = 1); 2002-2005 (n = 4); 2006-2010 (n = 10), and 2011-2016 (n = 24). Twenty-four underwent LT at a median age of 47.5 years (interquartile range, 37.0-58.5 years). Median calculated MELD score at time of LT was 8.0 (interquartile range, 7.0-9.5), and 75% received an exception MELD score. Two status-1 patients died during transplant surgery. Nineteen (86%) patients were alive after a median post-LT follow-up of 48 months, whereas 2 patients were lost to follow-up. Five of the aforementioned HHT patients underwent LT at Mayo Clinic, 4 with high output cardiac failure, and 1 with biliary ischemia. All 5 were alive at the time of last follow-up with good graft function and resolution of heart failure., Conclusions: Outcomes after LT for HHT patients are excellent with 86% survival after a median follow-up of 48 months and resolution of heart failure. LT listing for HHT has increased in substantially in more recent eras.
- Published
- 2019
- Full Text
- View/download PDF
15. Abdominal manifestations of hereditary hemorrhagic telangiectasia: a series of 333 patients over 15 years.
- Author
-
Welle CL, Welch BT, Brinjikji W, Ehman EC, Venkatesh SK, Johnson MP, Iyer VN, Leise MD, and Wood CP
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Contrast Media, Female, Humans, Intestine, Small blood supply, Intestine, Small diagnostic imaging, Liver blood supply, Liver diagnostic imaging, Male, Middle Aged, Pancreas blood supply, Pancreas diagnostic imaging, Radiographic Image Enhancement methods, Retrospective Studies, Spleen blood supply, Spleen diagnostic imaging, Young Adult, Abdomen blood supply, Abdomen diagnostic imaging, Arteriovenous Malformations diagnostic imaging, Arteriovenous Malformations etiology, Telangiectasia, Hereditary Hemorrhagic complications, Tomography, X-Ray Computed methods
- Abstract
Purpose: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant multi-organ vascular disorder that commonly affects the gastrointestinal tract and the liver resulting in telangiectasias and arteriovenous malformations (AVMs). Previous studies looking at the prevalence of liver and abdominal organ involvement in HHT have been limited by differing imaging techniques and sample size limitations. We sought to define the prevalence of HHT related abdominal vascular abnormalities using optimized multiphasic contrast-enhanced abdominal computed tomography (CT) exams in a large cohort of HHT patients., Methods: Between January 2001 and May 2015; we identified a total of 333 consecutive HHT patients who had undergone a dedicated HHT protocol multiphase abdominal CT at our institution. The CT exams were reviewed by three board certified abdominal radiologists for the presence of vascular abnormalities involving the liver, pancreas, spleen, and other abdominal organs. Vascular abnormalities involving the liver were further categorized as telangiectasias, large confluent vascular masses, perfusion abnormalities, or hepatic shunts., Results: In patients with abdominal vascular abnormalities, the liver was the most commonly involved organ, with 180 out of 333 (54.1%) patients demonstrating at least one hepatic vascular abnormality (telangiectasia, confluent vascular mass, transient perfusion abnormalities, and hepatic shunts), with most (70.0%) demonstrating multiple hepatic vascular abnormalities. The other most common organs involved included the pancreas (18.0%), spleen (6.3%), and small bowel (4.5%)., Conclusion: In patients with the clinical diagnosis of HHT, greater than half demonstrate an abdominal vascular abnormality, with the most commonly involved organ being the liver. These may be under recognized on routine or single phase contrast-enhanced CT of the abdomen. This supports the use of optimized multiphasic abdominal CT exams as an important tool for the evaluation and screening of patients with HHT.
- Published
- 2019
- Full Text
- View/download PDF
16. Risk of Post-transplant Hepatocellular Carcinoma Recurrence Is Higher in Recipients of Livers From Male Than Female Living Donors.
- Author
-
Han S, Yang JD, Sinn DH, Kim JM, Choi GS, Jung G, Ahn JH, Kim S, Ko JS, Gwak MS, Kwon CHD, Leise MD, Gwak GY, Heimbach JK, and Kim GS
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Propensity Score, Risk, Risk Factors, Sex Factors, Survival Analysis, Treatment Outcome, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular surgery, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Transplantation, Living Donors, Neoplasm Recurrence, Local pathology
- Abstract
Objective: To evaluate the relationship between donor sex and hepatocellular carcinoma (HCC) recurrence after living donor liver transplantation., Background: HCC shows a male predominance in incidence and recurrence after tumor resection due to sex differences in hepatic sex hormone receptors. There have been no studies evaluating the importance of donor sex on post-transplant HCC recurrence., Methods: Of 384 recipients of livers, from living donors, for HCC: 104/120 who received grafts from female donors were matched with 246/264 who received grafts from male donors using propensity score matching, with an unfixed matching ratio based on factors like tumor biology. Survival analysis was performed with death as a competing risk event. The primary outcome was overall HCC recurrence., Results: The median follow-up time was 39 months. Before matching, recurrence probability at 1/2/5 years after transplantation was 6.1/9.7/12.7% in recipients with female donors and 11.7/19.2/25.3% in recipients with male donors. Recurrence risk was significantly higher with male donors in univariable analysis (hazard ratio [HR] = 2.04 [1.15-3.60], P = 0.014) and multivariable analysis (HR=2.10 [1.20-3.67], P = 0.018). In the matched analysis, recurrence risk was also higher with male donors (HR=1.92 [1.05-3.52], P = 0.034): both in intrahepatic recurrence (HR=1.92 [1.05-3.51], P = 0.034) and extrahepatic recurrence (HR=1.93 [1.05-3.52], P = 0.033). Multivariable analysis confirmed the significance of donor sex (HR=2.08 [1.11-3.91], P = 0.023). Interestingly, the significance was lost when donor age was >40 years. Two external cohorts validated the significance of donor sex., Conclusions: Donor sex appears to be an important graft factor modulating HCC recurrence after living donor liver transplantation.
- Published
- 2018
- Full Text
- View/download PDF
17. Clinical and histopathologic manifestations of solid organ transplantation-associated graft-versus-host disease involving the skin: A single-center retrospective study.
- Author
-
Kim GY, Schmelkin LA, Davis MD, El-Azhary RA, Wieland CN, Leise MD, Meves A, and Lehman JS
- Subjects
- Adult, Aged, Female, Graft vs Host Disease mortality, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Graft vs Host Disease pathology, Organ Transplantation adverse effects, Skin Diseases pathology
- Abstract
Background: Graft-versus-host disease (GVHD) following solid organ transplantation (SOT) is extremely rare and infrequently described in the dermatologic literature., Methods: We performed a retrospective clinicopathologic review of our institution's experience with patients diagnosed with SOT-associated GVHD (SOT GVHD) (May 1, 1996 to September 1, 2017)., Results: Of nine patients with SOT GVHD, seven had undergone liver transplantation, while two had undergone lung transplantation. All presented initially with a skin eruption, which developed an average of 63 days (range: 11-162 days) post transplant. The average time to diagnosis following the onset of the skin eruption was 12 days (range: 0-54 days). Diagnosis was often delayed because of a competing diagnosis of drug reaction. Frequent skin findings included pruritic erythematous to violaceous macules and papules with desquamation. Histopathology showed vacuolar interface dermatitis in 12 of 15 cases (80.0%). Of the 11 specimens in which a hair follicle was present for evaluation, vacuolar interface changes around the hair follicle were present in eight (72.7%) cases. Seven patients (77.8%) died from complications during the follow-up period., Conclusions: SOT GVHD presents initially with skin involvement, is associated with vacuolar interface changes on skin biopsy, and is associated with a high mortality rate. Clinicopathologic correlation is required for accurate diagnosis., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
18. Assessment of the spectrum of hepatic encephalopathy: A multicenter study.
- Author
-
Reuter B, Walter K, Bissonnette J, Leise MD, Lai J, Tandon P, Kamath PS, Biggins SW, Rose CF, Wade JB, and Bajaj JS
- Subjects
- Ammonia blood, Biomarkers blood, Canada, Clinical Competence, Cognition, Diet, Protein-Restricted, Education, Medical, Graduate, Gastroenterology education, Health Care Surveys, Hepatic Encephalopathy blood, Hepatic Encephalopathy psychology, Hepatic Encephalopathy therapy, Humans, Patient Simulation, Practice Patterns, Nurses', Practice Patterns, Physicians', Predictive Value of Tests, Rifamycins therapeutic use, Rifaximin, Risk Factors, Severity of Illness Index, United States, Video Recording, Gastroenterologists education, Gastroenterologists trends, Hepatic Encephalopathy diagnosis, Liver Function Tests trends, Neuropsychological Tests, Nurse Practitioners trends, Physician Assistants trends
- Abstract
Hepatic encephalopathy (HE) is a major cause of morbidity in cirrhosis. However, its severity assessment is often subjective, which needs to be studied systematically. The aim was to determine how accurately trainee and nontrainee practitioners grade and manage HE patients throughout its severity. We performed a survey study using standardized simulated patient videos at 4 US and 3 Canadian centers. Participants were trainees (gastroenterology/hepatology fellows) and nontrainees (faculty, nurse practitioners, physician assistants). We determined the accuracy of HE severity identification and management options between grades <2 or ≥2 HE and trainees/nontrainees. In total, 108 respondents (62 trainees, 46 nontrainees) were included. For patients with grades <2 versus ≥2 HE, a higher percentage of respondents were better at correctly diagnosing grades ≥2 compared with grades <2 (91% versus 64%; P < 0.001). Specialized cognitive testing was checked significantly more often in grades <2, whereas more aggressive investigation for precipitating factors was ordered in HE grades >2. Serum ammonia levels were ordered in almost a third of grade ≥2 patients. For trainees and nontrainees, HE grades were identified similarly between groups. Trainees were less likely to order serum ammonia and low-protein diets, more likely to order rifaximin, and more likely to perform a more thorough workup for precipitating factors compared with nontrainee respondents. There was excellent concordance in the classification of grade ≥2 HE between nontrainees versus trainees, but lower grades showed discordance. Important differences were seen regarding blood ammonia, specialized testing, and nutritional management between trainees and nontrainees. These results have important implications at the patient level, interpreting multicenter clinical trials, and in the education of practitioners. Liver Transplantation 24 587-594 2018 AASLD., (© 2018 by the American Association for the Study of Liver Diseases.)
- Published
- 2018
- Full Text
- View/download PDF
19. Impact of Age on Outcomes in Hospitalized Patients with Hereditary Hemorrhagic Telangiectasia.
- Author
-
Iyer VN, Brinjikji W, Apala D, Pannu BS, Kotecha A, Leise MD, Kamath PS, Misra S, Lanzino G, Krowka MJ, Wood CP, and Swanson KL
- Abstract
Background: There is little published literature regarding the impact of age on outcomes amongst hospitalized HHT (hereditary hemorrhagic telangiectasia) patients., Methods: The Nationwide Inpatient Sample (NIS) was used to obtain data on all hospital discharges occurring in HHT patients from 2000 to 2012. The association between admission age and HHT-related complications and outcomes were studied., Results: 10293 hospitalizations in HHT patients from 2000 to 2012 were included. Patients > 50 accounted for 77% of all admissions with 30% of admissions occurring in the 51-65 age group. Bleeding related complications were the most frequent (62.7%, n = 6455 hospitalizations), followed by cardiovascular (41%, n = 4216), neurological (12.4%, n = 1276), and hepatobiliary (6.4%, n = 660) complications. Patients older than 50 accounted for 83% of bleeding events, 90% of cardiovascular events, 58% of neurologic events, and 81% of hepatobiliary events. The vast majority (83%) of medical and surgical procedures were performed in those older than 50 years of age. Older patients also experienced higher rates of death., Conclusion: Aging has significant adverse impacts on rates of hospitalization, complications, and outcomes amongst HHT patients in the United States. Except for neurologic complications, the vast majority of this disease burden is borne by patients older than 50 years.
- Published
- 2018
- Full Text
- View/download PDF
20. Relationship between portopulmonary hypertension and splenectomy: Mayo Clinic experience and review of published works.
- Author
-
Segraves JM, Cartin-Ceba R, Leise MD, and Krowka MJ
- Abstract
Aim: Portopulmonary hypertension is a serious complication of portal hypertension that can lead to right heart failure and death. To our knowledge, an association between portopulmonary hypertension and prior splenectomy has not been described previously. The goals of this study were to describe the frequency of splenectomy in portopulmonary hypertension and compare selected parameters between portopulmonary hypertension subgroups., Methods: This is a retrospective analysis of patients diagnosed with portopulmonary hypertension between 1 January 1988 and 30 June 2015 at Mayo Clinic (Rochester, MN, USA). We compared age, sex, right ventricle systolic pressure by echocardiography, and right heart catheterization measurements/calculations among subgroups of portopulmonary hypertension patients with splenectomy and/or autoimmune liver disease (autoimmune hepatitis/primary biliary cirrhosis/primary sclerosing cholangitis)., Results: The cohort consisted of 141 patients, of whom 8 (6%) had a history of splenectomy prior to the development of portopulmonary hypertension. Twenty-seven (19%) portopulmonary hypertension patients had autoimmune liver disease, and 5 of 8 (62.5%) splenectomized portopulmonary hypertension patients had autoimmune liver disease. No significant difference was noted in right heart catheterization measurements/calculations between splenectomized and non-splenectomized portopulmonary hypertension patients. Right ventricle systolic pressure by echocardiography was significantly higher in those splenectomized., Conclusions: Prior history of splenectomy in portopulmonary hypertension was 6% in this cohort. The combination of autoimmune liver disease and splenectomy in portopulmonary hypertension was not uncommon. History of splenectomy in patients with portal hypertension and/or autoimmune liver disease may have clinical implications., (© 2017 The Japan Society of Hepatology.)
- Published
- 2018
- Full Text
- View/download PDF
21. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
- Author
-
Iyer VN, Apala DR, Pannu BS, Kotecha A, Brinjikji W, Leise MD, Kamath PS, Misra S, Begna KH, Cartin-Ceba R, DuBrock HM, Krowka MJ, O'Brien EK, Pruthi RK, Schroeder DR, and Swanson KL
- Subjects
- Administration, Intravenous, Aged, Angiogenesis Inhibitors administration & dosage, Female, Ferritins blood, Humans, Male, Middle Aged, Minnesota, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Anemia, Refractory diagnosis, Anemia, Refractory etiology, Anemia, Refractory therapy, Bevacizumab administration & dosage, Epistaxis diagnosis, Epistaxis etiology, Epistaxis therapy, Gastrointestinal Hemorrhage diagnosis, Gastrointestinal Hemorrhage etiology, Gastrointestinal Hemorrhage therapy, Quality of Life, Telangiectasia, Hereditary Hemorrhagic blood, Telangiectasia, Hereditary Hemorrhagic complications, Telangiectasia, Hereditary Hemorrhagic diagnosis, Telangiectasia, Hereditary Hemorrhagic psychology
- Abstract
Objective: To present a multiyear clinical experience with intravenous bevacizumab for the management of severe gastrointestinal bleeding and/or epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)., Patients and Methods: All patients treated with intravenous bevacizumab for severe hereditary hemorrhagic telangiectasia-related bleeding from June 1, 2013, through January 31, 2017, were included in this report. Severity of epistaxis (determined using the Epistaxis Severity Score questionnaire); hemoglobin, iron, and ferritin levels; and quality of life data were collected serially in all patients., Results: Intravenous bevacizumab was administered to 34 patients using a standardized treatment protocol. Anemia was primarily related to severe epistaxis (n=15, 44%), severe gastrointestinal bleeding (n=4, 12%), or both (n=15, 44%), with a median baseline hemoglobin level of 9.1 g/dL (range, 8.3-10.5 gm/dL; to convert to mmol/L, multiply by 0.62). Red blood cell (RBC) transfusions had been administered to 28 patients (82%). Of these, 16 patients (47%) were RBC transfusion dependent and had received a median of 75 RBC transfusions (range, 4->500 RBC units) before bevacizumab initiation. The median length of follow-up was 17.6 months from the beginning of bevacizumab treatment (range, 3-42.5 months). There was a significant reduction in epistaxis severity scores (P<.001) and RBC transfusion requirements (P=.007) after completion of the initial bevacizumab treatment cycle. New-onset or worsened hypertension was noted in 4 patients, with 1 patient experiencing hypertensive urgency with a temporary decline in renal function., Conclusion: Intravenous bevacizumab is an effective treatment option for patients with severe anemia related to epistaxis and/or gastrointestinal bleeding. Further studies are needed to establish a dose-response relationship as well as clinical, genetic, and biomarker predictors of response., (Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
22. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation.
- Author
-
Han S, Lee S, Yang JD, Leise MD, Ahn JH, Kim S, Jung K, Gwak MS, Kim GS, and Ko JS
- Subjects
- Adult, Carcinoma, Hepatocellular blood, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular pathology, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Liver Neoplasms blood, Liver Neoplasms epidemiology, Liver Neoplasms pathology, Liver Transplantation methods, Living Donors, Male, Middle Aged, Neoplasm Recurrence, Local blood, Neoplasm Recurrence, Local pathology, Preoperative Period, Propensity Score, Risk Factors, Treatment Outcome, Young Adult, Carcinoma, Hepatocellular surgery, Liver Neoplasms surgery, Liver Transplantation adverse effects, Neoplasm Recurrence, Local epidemiology, Platelet Count
- Abstract
Platelets interact with tumor cells and promote metastasis. The importance of platelets in posttransplant hepatocellular carcinoma (HCC) recurrence is unclear. Thus, we aimed to evaluate the association between preoperative platelet count (PLT) and HCC recurrence after living donor liver transplantation. Of 359 recipients of livers from living donors for HCC, 209 of 240 patients who had preoperative PLT ≤75 × 10
9 /L were matched with 97 of 119 patients who had preoperative PLT >75 × 109 /L using propensity score matching, with an unfixed matching ratio based on factors such as tumor biology. The cutoff value of 75 × 109 /L was set based on optimum stratification analysis. Survival analysis was performed with death as a competing risk event. The primary outcome was overall HCC recurrence. The median follow-up time was 59 months. Before matching, recurrence probability at 1, 2, and 5 years after transplantation was 4.7%, 9.2%, and 11.3% for the low platelet group and 14.5%, 23.0%, and 30.5% for the high platelet group. Recurrence risk was significantly greater in the high platelet group in both univariate (hazard ratio [HR] = 3.09; 95% confidence interval [CI], 1.86-5.14; P < 0.001) and multivariate analyses (HR = 2.10; 95% CI, 1.23-3.60; P = 0.007). In the matched analysis, recurrence risk was also greater in the high platelet group in both univariate (HR = 2.33; 95% CI, 1.36-4.01; P = 0.002) and multivariate analyses (HR = 1.90; 95% CI, 1.02-3.54; P = 0.04). Preoperative PLT had no interaction with the Milan criteria, alpha-fetoprotein level, Edmonson grade, microvascular invasion, or intrahepatic metastasis. Incorporation of preoperative PLT into the Milan criteria significantly improved predictive power. Inflammation-based scores including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and the inflammation-based index did not show superiority to preoperative PLT in predicting HCC recurrence. In conclusion, preoperative PLT appears to be an important host factor affecting HCC recurrence after living donor liver transplantation. Liver Transplantation 24 44-55 2018 AASLD., (© 2017 by the American Association for the Study of Liver Diseases.)- Published
- 2018
- Full Text
- View/download PDF
23. Reply to: "Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
- Author
-
Yang JD and Leise MD
- Subjects
- Hepacivirus, Humans, Neoplasm Recurrence, Local, Carcinoma, Hepatocellular, Hepatitis C, Liver Neoplasms
- Published
- 2017
- Full Text
- View/download PDF
24. Reply.
- Author
-
Yang JD and Leise MD
- Subjects
- Humans, Interrupted Time Series Analysis, Antiviral Agents, Medicaid
- Published
- 2017
- Full Text
- View/download PDF
25. Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis.
- Author
-
Haffar S, Bazerbachi F, Leise MD, Dillon JJ, Albright RC, Murad MH, Kamath PS, and Watt KD
- Subjects
- Hepatitis E epidemiology, Hepatitis E virus immunology, Humans, Prevalence, Seroepidemiologic Studies, Hepatitis Antibodies blood, Hepatitis E blood, Immunoglobulin G blood, Renal Dialysis
- Abstract
Background: Hepatitis E virus (HEV) infection appears to be more common than previously thought. HEV seroprevalence in patients on maintenance haemodialysis (HD) is unclear with a range from 0% to 44%. In addition, risk factors of transmission of HEV in patients on haemodialysis are unknown., Aim: To perform a systematic review and meta-analysis of HEV seroprevalence in HD patients compared with controls., Methods: A systematic search of several databases identified all observational studies with comparative arms. Two reviewers extracted data and assessed the methodological quality. A random-effects model was used for pooled odds ratio (OR) and 95% confidence interval (CI) of positive anti-HEV IgG in both groups. Heterogeneity and publication bias were assessed with appropriate tests., Results: We identified 31 studies from 17 countries between 1994 and 2016. Sixteen studies were judged to have adequate quality and 15 to have moderate limitations. HEV infection was more prevalent in patients on haemodialysis compared with controls (OR 2.47, 95% CI 1.79-3.40, I
2 = 75.2%, P < .01). We conducted several subgroup analyses without difference in results. Egger regression test did not suggest publication bias (P = .83). Specific risk factors of HEV transmission in patients on haemodialysis were not clearly identified., Conclusions: Hepatitis E virus infection is more prevalent in patients on haemodialysis compared with non-haemodialysis control groups. Further studies are needed to determine risk factors of acquisition, impact on health, and risk for chronic HEV especially among those patients going to receive organ transplantation., (© 2017 John Wiley & Sons Ltd.)- Published
- 2017
- Full Text
- View/download PDF
26. Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?
- Author
-
Bazerbachi F, Leise MD, Watt KD, Murad MH, Prokop LJ, and Haffar S
- Abstract
Background and aim: Mixed cryoglobulinemia (MC) has been associated with several viral infections, and chronic hepatitis C is recognized as a major cause. MC associated with hepatitis E virus (HEV) has been described and little is known about this rare association. The aim of this study is to perform a systematic review of MC associated with HEV, and examine the presence of a causal relationship. Methods: An experienced librarian conducted a search of databases from each database's inception to 12 December 2016 based on a priori criteria. The risk of bias was assessed, and Hill's criteria were applied to determine causality. Results: Five publications met inclusion criteria, with a total of 15 cases. Three studies had low, one low to moderate and one moderate risk of bias. Median age was 43 years, and all patients came from Western Europe. Two patients were immunocompetent, while 13 were immunosuppressed, post solid organ transplant and had chronic hepatitis E. Renal involvement was observed in seven patients, mild to moderately severe cryoglobulinemic disease in one patient and severe cryoglobulinemic disease in three patients. One patient improved spontaneously, and another was treated with immunosuppressant reduction leading to viral clearance. Ten patients treated with peg-interferon or ribavirin for 3 months achieved loss of cryoglobulinemia and end-of-treatment response, but sustained virologic response was reported and achieved in two. Immunosuppressant achieved loss of cryoglobulinemia in three patients. One case of chronic renal failure, three cases of end-stage renal disease and one death were observed. Five of the nine Hill's criteria were fulfilled. Conclusion: MC has been described with HEV infection. A causal relationship between HEV infection and cryoglobulinemia is highly probable.
- Published
- 2017
- Full Text
- View/download PDF
27. Damned if you do, damned if you don't: The evolving story of de novo and recurrent hepatocellular carcinoma amongst those treated with direct-acting antivirals for hepatitis C virus.
- Author
-
Yang JD and Leise MD
- Subjects
- Antiviral Agents adverse effects, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular pathology, Clinical Decision-Making, Hepatitis C, Chronic diagnosis, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Humans, Incidence, Liver Neoplasms epidemiology, Liver Neoplasms pathology, Liver Neoplasms surgery, Liver Transplantation, Patient Selection, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Antiviral Agents therapeutic use, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular virology, Hepatitis C, Chronic drug therapy, Liver Neoplasms virology, Neoplasm Recurrence, Local
- Published
- 2017
- Full Text
- View/download PDF
28. Hyponatremia in the perioperative period: When and how to correct.
- Author
-
Leise MD and Findlay JY
- Published
- 2017
- Full Text
- View/download PDF
29. Interpreting Outcomes in DCDD Liver Transplantation: First Report of the Multicenter IDOL Consortium.
- Author
-
Goldberg DS, Karp SJ, McCauley ME, Markmann JF, Croome KP, Taner CB, Heimbach JK, Leise MD, Fryer JP, Bohorquez HE, Cohen AJ, Gilroy RK, Kumer SC, Foley DP, Karim AS, Hernandez-Alejandro R, Levstik MA, and Abt PL
- Subjects
- Adult, Aged, Cause of Death, Databases, Factual, Female, Humans, Male, Middle Aged, Multivariate Analysis, Outcome Assessment, Health Care, Retrospective Studies, Risk Factors, United States, Bile Duct Diseases etiology, Bile Ducts, Intrahepatic blood supply, Donor Selection methods, Ischemia etiology, Liver Transplantation methods, Postoperative Complications etiology, Tissue Donors
- Abstract
Background: In the United States, 5% of adult liver transplant recipients receive a graft donation after circulatory determination of death (DCDD). Concerns for ischemic cholangiopathy (IC), a disease of diffuse intrahepatic stricturing limits broader DCDD use. Single-center reports demonstrate large variation in outcomes., Methods: Retrospective deidentified data collected between 2005 and 2013 were entered electronically by 10 centers via a Research Electronic Data Capture database. Our primary outcome was development of intrahepatic biliary strictures consistent with IC., Results: Within 6 months post-DCDD transplant, 162 (21.8%) patients developed a biliary stricture, of which 88 (11.8%) exhibited intrahepatic structuring consistent with IC. Unadjusted 6-month IC rate among the 10 centers varied significantly (P = 0.006) from 6.3% to 25.9%. The only factor associated with increased risk of IC within 6 months was Roux-en-Y hepaticojejunostomy (vs duct-to-duct) (odds ratio, 3.06; 95% confidence interval, 1.52-6.16; P = 0.002). Graft failure by 6 months was more than 3 times higher for DCDD recipients with IC (odds ratio for IC, 3.36; 95% confidence interval, 1.95-5.79)., Conclusions: This first report of the large combined experience with DCDD from the Improving DCDD Outcomes in Liver Transplant consortium demonstrates significant differences in IC among centers, the importance of biliary strictures as a risk factor for graft failure, and does not validate other risk factors for IC found in smaller studies.
- Published
- 2017
- Full Text
- View/download PDF
30. Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States.
- Author
-
Yang JD, Larson JJ, Watt KD, Allen AM, Wiesner RH, Gores GJ, Roberts LR, Heimbach JA, and Leise MD
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Retrospective Studies, United States epidemiology, Waiting Lists, Young Adult, Carcinoma, Hepatocellular epidemiology, Carcinoma, Hepatocellular surgery, Liver Failure etiology, Liver Failure surgery, Liver Transplantation
- Abstract
Background & Aims: Management strategies for patients with hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC) have changed, along with liver allocation policies based on model for end-stage liver disease score. We investigated etiologic-specific trends in liver transplantation in the United States during different time periods., Methods: We performed a retrospective study, using the United Network for Organ Sharing/Organ Procurement and Transplantation Network registry data, to identify all adult patients registered for liver transplantation in the United States from January 1, 2004, through December 31, 2015. For subjects listed with multiple diagnoses, HCC was considered the primary listing diagnosis. To determine whether availability of direct-acting antiviral agents, which began in 2011, affected pretransplant (death or drop-out) and post-transplant outcomes for patients with HCV infection, we compared data from the time periods of 2004 to 2010 and 2011 to 2014. We used competing-risk analysis to compare differences in end points between these periods. Differences between periods in pretransplantation and post-transplantation outcomes were estimated using Kaplan-Maier analysis and compared using the log-rank test. Associations between year of listing and pre-liver transplant outcome, and year of liver transplant and survival after transplant, were examined using the log-rank test. Proportional hazard regression was used to evaluate the reliability of the time period effect with potential confounders., Results: Among 109,018 registrants, 18.5% were registered for liver transplantation because of HCC. In 2015, HCC was the leading diagnosis among registrants (23.9% of registrations) and recipients (27.2% of recipients). Between 2004 and 2015, the ratio of registrants with vs without HCC increased 5.6-fold for patients with HCV infection, 1.9-fold for patients with hepatitis B virus (HBV) infection, 2.7-fold for patients with alcohol abuse, and 10.2-fold for patients with nonalcoholic steatohepatitis. After adjusting for covariates, we associated the period of 2011 to 2014 with a decreased probability that HCC registrants would undergo liver transplantation (hazard ratio [HR], 0.62; P < .0001). The period of 2011 to 2014 also was associated with a decreased probability of drop-out owing to deterioration or death from HCV-induced (HR, 0.90; P = .0003), HBV-induced (HR, 0.71; P = .002), or alcohol-induced (HR, 0.90; P = .01) liver disease, and an increased probability of delisting as a result of clinical improvement in patients with HCV infection (HR, 3.4; P < .0001), HBV infection (HR, 2.3; P = .004), or alcohol abuse (HR, 2.2; P < .0001). The period of 2011 to 2014 was associated with a decreased risk of graft loss or death, with the largest effect seen in HCV-infected recipients (HR, 0.76; P < .0001)., Conclusions: HCC was the leading indication for liver transplantation in the United States in 2015. Despite this, the probability of liver transplantation decreased the most in registrants with HCC. Pretransplantation and post-transplantation outcomes have improved, particularly in patients with HCV infection., (Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
31. Factors Influencing Surveillance for Hepatocellular Carcinoma in Patients with Liver Cirrhosis.
- Author
-
Ahmed Mohammed HA, Yang JD, Giama NH, Choi J, Ali HM, Mara KC, Harmsen WS, Wiesner RH, Leise MD, Therneau TM, and Roberts LR
- Abstract
Objective: Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related mortality worldwide, and a rising cause of cancer mortality in the U.S. Liver cirrhosis is the major risk factor for HCC. Surveillance of persons with cirrhosis facilitates early detection and improves outcomes. We assessed the surveillance rate for HCC within a major academic health system and identified factors influencing surveillance., Patients and Methods: We examined the surveillance rate for HCC using liver ultrasound, CT, or MRI, and factors influencing surveillance in a cohort of 369 Minnesota residents with cirrhosis seen at the Mayo Clinic between 2007 and 2009., Results: Ninety-three percent of cirrhosis patients received at least one surveillance study, but only 14% received the recommended uninterrupted semiannual surveillance. Thirty percent received ≥75% of recommended surveillance, and 59% received ≥50% of recommended surveillance. Factors increasing surveillance included gastroenterology or hepatology specialist visits (p < 0.0001), advanced liver disease as assessed by hepatic encephalopathy (p = 0.0008), and comorbid illness as assessed by diabetes mellitus (p = 0.02). Age, sex, race, residence, cirrhosis etiology, or number of primary care visits did not significantly affect the rate of surveillance., Conclusions: While the rate of surveillance in a major academic health system was higher than reported in other studies, surveillance was heavily dependent on visits to a subspecialist. This suggests a major and urgent national need to improve identification of individuals at risk for HCC in the primary care setting and the initiation and maintenance of surveillance by primary care practitioners.
- Published
- 2017
- Full Text
- View/download PDF
32. Reply.
- Author
-
Lynn AM and Leise MD
- Published
- 2016
- Full Text
- View/download PDF
33. The Effects of Supplementation with p-Synephrine Alone and in Combination with Caffeine on Metabolic, Lipolytic, and Cardiovascular Responses during Resistance Exercise.
- Author
-
Ratamess NA, Bush JA, Kang J, Kraemer WJ, Stohs SJ, Nocera VG, Leise MD, Diamond KB, Campbell SC, Miller HB, and Faigenbaum AD
- Subjects
- Adult, Blood Glucose analysis, Cross-Over Studies, Dietary Supplements, Double-Blind Method, Energy Metabolism drug effects, Fatty Acids, Nonesterified blood, Glycerol blood, Heart Rate drug effects, Humans, Lipolysis drug effects, Male, Metabolism drug effects, Oxygen Consumption drug effects, Caffeine administration & dosage, Cardiovascular System drug effects, Exercise physiology, Resistance Training, Synephrine administration & dosage
- Abstract
Objective: The purpose of this study was to examine the metabolic, lipolytic, and cardiovascular responses to supplementation with p-synephrine alone and in combination with caffeine during resistance exercise (RE)., Methods: Twelve healthy men performed a control RE protocol (6 × 10 repetitions of squats) and were randomly assigned (using a double-blind crossover design with random protocol sequencing) to a supplement sequence: p-synephrine (S; 100 mg), p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine), or a placebo (P). Subjects reported to the lab at a standard time, consumed a supplement, sat quietly for 45 minutes, performed the RE protocol, and sat quietly for 30 minutes. Blood samples were collected at rest (T1), after sitting quietly for 45 minutes (T2), immediately following RE (T3), and 15 minutes (T4) and 30 minutes (T5) postexercise. Oxygen consumption (VO
2 ) and heart rate (HR) data were collected throughout., Results: Serum glycerol was significantly elevated at T2 only in S and SCF and T3 to T5 in all treatments. Nonesterified fatty acid (NEFA) concentrations did not differ between treatments. Plasma glucose was significantly elevated compared to T1 with highest area under the curve values seen in SCF. Mean VO2 and energy expenditure (EE) were significantly higher in S and SCF through 30 minutes postexercise. Fat oxidation rates favored S and SCF between 25 and 30 minutes postexercise. Mean HR during RE was significantly highest in SCF., Conclusions: Supplementation with S and SCF increases lipolysis primarily at rest and increases VO2 , EE, and fat oxidation rates 30 minutes following RE. No HR changes were observed unless caffeine was added.- Published
- 2016
- Full Text
- View/download PDF
34. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.
- Author
-
Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, and Leise MD
- Subjects
- Antiviral Agents, Hepatitis C, Hepatitis C, Chronic, Humans, Liver Neoplasms, Neoplasm Recurrence, Local, Recurrence, Carcinoma, Hepatocellular, Liver Transplantation
- Published
- 2016
- Full Text
- View/download PDF
35. Evaluation of liver stiffness with magnetic resonance elastography in patients with constrictive pericarditis: Preliminary findings.
- Author
-
Fenstad ER, Dzyubak B, Oh JK, Williamson EE, F Glockner J, Young PM, Anavekar NS, Leise MD, Ehman RL, Araoz PA, and Venkatesh SK
- Subjects
- Elastic Modulus, Female, Humans, Image Enhancement methods, Male, Middle Aged, Pilot Projects, Reproducibility of Results, Sensitivity and Specificity, Stress, Mechanical, Elasticity Imaging Techniques methods, Image Interpretation, Computer-Assisted methods, Liver diagnostic imaging, Liver physiopathology, Magnetic Resonance Imaging methods, Pericarditis, Constrictive diagnosis, Pericarditis, Constrictive physiopathology
- Abstract
Purpose: To evaluate with magnetic resonance elastography (MRE) whether patients with constrictive pericarditis (CP) have increased hepatic stiffness. CP results in reduced pericardial compliance, ventricular interdependence, and right heart failure. Patients with untreated CP may develop liver fibrosis and ultimately cirrhosis due to chronic venous congestion. Chronic venous congestion ± fibrosis may lead to increased liver stiffness., Materials and Methods: Prospectively, patients with suspected CP underwent 2D transthoracic echocardiography, cardiac MRI, and liver MRE. An automated method was used to draw regions of interest (ROIs) on the stiffness maps to calculate the mean liver stiffness in kilopascals (kPa). A t-test with α = 0.05 was performed between stiffness values of patients with positive and negative CP findings based on previously published echocardiography criteria., Results: Nineteen patients met inclusion criteria with a mean ± standard deviation (SD) age of 51 ± 16 years. Nine patients (47%) had CP. Mean liver stiffness trended higher in patients with CP compared to those without CP (4.04 kPa vs. 2.46; P = 0.045). Liver stiffness correlated with MRI septal bounce (P = 0.04), inferior vena cava size (P = 0.003), echo abnormal septal motion (P = 0.04), and echo mitral inflow variation >25% (P = 0.02). Only MRI septal bounce predicted CP by echocardiography (P < 0.001)., Conclusion: CP was associated with increased liver stiffness. The increased stiffness is most likely secondary to chronic hepatic venous congestion and/or fibrosis. MRE may be useful for noninvasive liver stiffness assessment in CP. J. Magn. Reson. Imaging 2016;44:81-88., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
36. Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy.
- Author
-
Lynn AM, Singh S, Congly SE, Khemani D, Johnson DH, Wiesner RH, Kamath PS, Andrews JC, and Leise MD
- Subjects
- Aged, Ascites epidemiology, Ascites etiology, Drug Resistance, Embolization, Therapeutic adverse effects, Feasibility Studies, Female, Hepatic Encephalopathy etiology, Humans, Hypertension, Portal epidemiology, Hypertension, Portal etiology, Male, Middle Aged, Recurrence, Retrospective Studies, Severity of Illness Index, Tertiary Care Centers, Treatment Outcome, Embolization, Therapeutic methods, End Stage Liver Disease complications, Hepatic Encephalopathy therapy, Liver Cirrhosis complications, Patient Selection, Portal Vein abnormalities, Vascular Malformations therapy
- Abstract
Treatment options for refractory hepatic encephalopathy (HE) are limited. Patients who fail medical management may harbor large portosystemic shunts (PSSs) which are possible therapeutic targets. This study aims to describe patient selection, effectiveness, and safety of percutaneous PSS embolization in those with medically refractory HE. A retrospective evaluation of consecutive adult patients with medically refractory HE referred for PSS embolization at a tertiary center was performed (2003-2015). Patient data collected included the type of HE, medications, Model for End-Stage Liver Disease (MELD) score, shunt type, embolization approach, and materials used. Outcomes of interest were immediate (7 days), intermediate (1-4 months), and longer-term (6-12 months) effectiveness and periprocedural safety. Effectiveness was determined based on changes in hospitalization frequency, HE medications, and symptoms. Twenty-five patients with large PSS were evaluated for shunt embolization. Five were excluded due to high MELD scores (n = 1), comorbid conditions (n = 1), or technical considerations (n = 3). Of 20 patients who underwent embolization, 13 had persistent and 7 had recurrent HE; 100% (20/20) achieved immediate improvement. Durable benefit was achieved in 100% (18/18) and 92% (11/12) at 1-4 and 6-12 months, respectively. The majority (67%; 8/12) were free from HE-related hospitalizations over 1 year; 10% developed procedural complications, and all resolved. Six developed new or worsening ascites. In conclusion, PSS embolization is a safe and effective treatment strategy that should be considered for select patients with medically refractory HE. Liver Transplantation 22 723-731 2016 AASLD., (© 2016 American Association for the Study of Liver Diseases.)
- Published
- 2016
- Full Text
- View/download PDF
37. The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know.
- Author
-
Doycheva I, Leise MD, and Watt KD
- Subjects
- Animals, Bacteria classification, Bacteria immunology, Bacterial Translocation, Dysbiosis, Graft Rejection immunology, Graft Rejection microbiology, Host-Pathogen Interactions, Humans, Immunocompromised Host, Immunosuppressive Agents adverse effects, Intestines immunology, Liver Cirrhosis immunology, Liver Cirrhosis microbiology, Risk Factors, Treatment Outcome, Bacteria pathogenicity, Gastrointestinal Microbiome, Intestines microbiology, Liver Cirrhosis surgery, Liver Transplantation adverse effects
- Abstract
The intestinal microbiome and immune system are in close symbiotic relationship in health. Gut microbiota plays a role in many chronic liver diseases and cirrhosis. However, alterations in the gut microbiome after liver transplantation and the implications for liver transplant recipients are not well understood and rely mainly on experimental animal studies. Recent advances in molecular techniques have identified that increased intestinal permeability, decreased beneficial bacteria, and increased pathogenic species may play important roles in the early posttransplant period. The associations between microbiota perturbation and postliver transplant infections and acute rejection are evolving. The link with metabolic syndrome, obesity, and cardiac disease in the general population require translation into the transplant recipient. This review focuses on our current knowledge of the known and potential interaction of the microbiome in the liver transplant recipient. Future human studies focused on microbiota changes in liver transplant patients are warranted and expected.
- Published
- 2016
- Full Text
- View/download PDF
38. The effects of supplementation with P-Synephrine alone and in combination with caffeine on resistance exercise performance.
- Author
-
Ratamess NA, Bush JA, Kang J, Kraemer WJ, Stohs SJ, Nocera VG, Leise MD, Diamond KB, and Faigenbaum AD
- Subjects
- Athletic Performance, Caffeine administration & dosage, Dietary Supplements, Double-Blind Method, Humans, Isometric Contraction physiology, Male, Muscle Strength physiology, Muscle, Skeletal physiology, Oxygen Consumption, Physical Endurance physiology, Synephrine administration & dosage, Young Adult, Caffeine pharmacology, Isometric Contraction drug effects, Muscle Strength drug effects, Muscle, Skeletal drug effects, Physical Endurance drug effects, Resistance Training, Synephrine pharmacology
- Abstract
Background: Little is known concerning the potential ergogenic effects of p-synephrine supplementation. Therefore, the purpose of the present study was to examine the effects of supplementation with p-synephrine alone and in combination with caffeine on free-weight resistance exercise performance., Methods: Twelve healthy, college-aged men performed a control (CT) resistance exercise protocol consisting of 6 sets of squats for up to 10 repetitions per set using 80% of their one repetition-maximum (1RM) with 2 min of rest in between sets. Each subject was randomly assigned (in double-blind, balanced manner) to a treatment sequence consisting of use of 3 supplements: p-synephrine (S; 100 mg), p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine), or a placebo (P). For each supplement treatment (separated by 1 week), subjects consumed the supplement for 3 days prior to each protocol and the morning of each protocol, and subsequently did not consume any supplements for 3 days following (i.e. wash-out period). On each protocol day, subjects reported to the lab at a standard time, consumed a supplement, sat quietly for 45 min, performed the resistance exercise protocol, and sat quietly for 30 min post exercise. Performance (repetition number, force, velocity and power), blood lactate, and ratings of perceived exertion (RPE) data were collected during each protocol., Results: Supplements SCF and S produced a significantly (P < 0.05) greater number of repetitions performed than CT (by 11.0 ± 8.0%) and P (by 6.0 ± 7.0%) and a 10.6 ± 12.0% greater increase in volume load per protocol than CT and P. Most of the differences were seen during the last 3 sets. Mean power and velocity for all 6 sets were significantly higher in SCF compared to CT and P by ~6.2 ± 8.0%. No supplement effects were observed in RPE or blood lactate, and no adverse side effects were observed or reported., Conclusions: S and SCF augmented resistance exercise performance (total repetitions, volume load) without increasing blood lactate or RPE. The addition of caffeine in SCF increased mean power and velocity of squat performance. These results indicate supplementation with S and SCF can enhance local muscle endurance during resistance exercise.
- Published
- 2015
- Full Text
- View/download PDF
39. Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk.
- Author
-
Fussner LA, Heimbach JK, Fan C, Dierkhising R, Coss E, Leise MD, and Watt KD
- Subjects
- Adult, Biomarkers, Body Mass Index, Comorbidity, Cyclosporine therapeutic use, Diabetes Complications, End Stage Liver Disease complications, Female, Glomerular Filtration Rate, Humans, Hypertension complications, Immunosuppression Therapy, Incidence, Male, Metabolic Syndrome complications, Middle Aged, Obesity complications, Odds Ratio, Prevalence, Proportional Hazards Models, Retrospective Studies, Risk Factors, Tacrolimus therapeutic use, Cardiovascular Diseases complications, End Stage Liver Disease surgery, Liver Transplantation adverse effects
- Abstract
The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8- to 12-year follow-up was performed. Obesity increased from 23.8% (4 months) to 40.8% (3 years) after LT. Increase in body mass index predicted MS at 1 year after LT (odds ratio, 1.1; P < 0.001, per point). CVD developed in 10.6%, 20.7%, and 30.3% of recipients within 1, 5, and 8 years, respectively. Age, diabetes, hypertension, glomerular filtration rate < 60 mL/minute, prior CVD, ejection fraction < 60%, left ventricular hypertrophy, and serum troponin (TN) > 0.07 ng/mL were associated with CVD on univariate analysis. Age (hazard ratio [HR], 1.03; 95% confidence interval [CI], 1.01-1.06; P = 0.019), diabetes (HR, 1.78; 95% CI, 1.09-2.92; P = 0.022), prior history of CVD (HR, 2.46; 95% CI, 1.45-4.16; P < 0.001), and serum TN > 0.07 ng/mL (HR, 1.98; 95% CI, 1.23-3.18; P = 0.005) were independently associated with CVD in the long term. Smoking history (ever), sex, hyperlipidemia, and serum ferritin levels were not predictive of CVD. Tacrolimus use versus noncalcineurin-based immunosuppression (HR, 0.26; 95% CI, 0.14-0.49; P < 0.001) was associated with reduced risk of CVD but not versus cyclosporine (HR, 0.67; 95% CI, 0.30-1.49; P = 0.322). CVD is common after LT. Independent of MS, more data are needed to identify nonconventional risk factors and biomarkers like serum TN. Curbing weight gain in the early months after transplant may impact MS and subsequent CVD in the long term., (© 2015 American Association for the Study of Liver Diseases.)
- Published
- 2015
- Full Text
- View/download PDF
40. 64-year-old woman with diarrhea and increased abdominal girth.
- Author
-
Shih HH, Law RJ, and Leise MD
- Subjects
- Ascites diagnosis, Ascites therapy, Female, Hematologic Neoplasms diagnosis, Hematologic Neoplasms therapy, Humans, Hypertension, Portal diagnosis, Hypertension, Portal therapy, Mastocytosis, Systemic diagnosis, Mastocytosis, Systemic therapy, Middle Aged, Ascites etiology, Diarrhea etiology, Hematologic Neoplasms complications, Hypertension, Portal complications, Mastocytosis, Systemic complications, Waist Circumference
- Published
- 2015
- Full Text
- View/download PDF
41. From vitamin K antagonists to liver international normalized ratio: a historical journey and critical perspective.
- Author
-
Gatt A, Chen D, Pruthi RK, Kamath PS, Leise MD, Ashrani AA, Nichols WL, and He R
- Subjects
- Animals, Anticoagulants pharmacology, History, 20th Century, History, 21st Century, Humans, Liver Diseases therapy, Prothrombin Time, Warfarin pharmacology, International Normalized Ratio history, Liver Diseases blood, Vitamin K antagonists & inhibitors
- Abstract
Adoption of international normalized ratio (INR) to harmonize prothrombin time has greatly improved the safety and effectiveness of vitamin K antagonists (VKA) oral anticoagulant therapy. INR is also a major laboratory variable in calculating the widely used Model for End-Stage Liver Disease (MELD) score for liver transplant organ prioritization. However, since the conventional INR (INRVKA) is calibrated specifically for VKA patients, its interlaboratory variation has a significant impact on the accuracy of MELD score. Though still requiring further clinical validation in large numbers of waitlisted patients, the alternative liver INR calibrated by using plasma from liver disease patients instead of VKA patients may harmonize the differences and thus more suitable for MELD score calculation. The objective of this article is to review the history of INR, MELD score, and liver INR, and discuss the challenges and solutions of liver INR implementation., (Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.)
- Published
- 2014
- Full Text
- View/download PDF
42. Living donor liver transplantation: Alive and well.
- Author
-
Leise MD
- Subjects
- Female, Humans, Male, Liver Transplantation mortality, Living Donors
- Published
- 2014
- Full Text
- View/download PDF
43. Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system.
- Author
-
Leise MD, Leung N, El-Zoghby Z, Gonzalez Gonzalez HC, Cerhan JH, and Nyberg SL
- Subjects
- Abdominal Abscess etiology, Aged, Albumins chemistry, Catheterization, Humans, Hypertension, Portal etiology, Male, Peritonitis microbiology, Portal Vein pathology, Postoperative Period, Reoperation, Treatment Outcome, Venous Thrombosis etiology, Carcinoma, Hepatocellular therapy, End Stage Liver Disease therapy, Hepatic Encephalopathy therapy, Liver Cirrhosis therapy, Liver Neoplasms therapy, Renal Dialysis methods, Sorption Detoxification methods
- Published
- 2014
- Full Text
- View/download PDF
44. Effect of the pretransplant serum sodium concentration on outcomes following liver transplantation.
- Author
-
Leise MD, Yun BC, Larson JJ, Benson JT, Yang JD, Therneau TM, Rosen CB, Heimbach JK, Biggins SW, and Kim WR
- Subjects
- Biomarkers blood, Female, Hospital Mortality, Humans, Hypernatremia blood, Hypernatremia diagnosis, Hypernatremia mortality, Hyponatremia blood, Hyponatremia diagnosis, Hyponatremia mortality, Kaplan-Meier Estimate, Length of Stay, Liver Failure blood, Liver Failure complications, Liver Failure diagnosis, Liver Failure mortality, Liver Transplantation adverse effects, Liver Transplantation mortality, Male, Middle Aged, Proportional Hazards Models, Registries, Risk Factors, Time Factors, Treatment Outcome, Hypernatremia complications, Hyponatremia complications, Liver Failure surgery, Sodium blood
- Abstract
Hyponatremia is associated with an increased risk of mortality on the liver transplantation (LT) waiting list. Although the incorporation of the serum sodium (Na) level into the Model for End-Stage Liver Disease score may reduce wait-list mortality, concerns remain about a potential association between pre-LT hyponatremia and decreased post-LT survival. Furthermore, the relationship between pre-LT hypernatremia and post-LT survival remains unexplored. The purpose of this study was to investigate the impact of the entire spectrum of pre-LT serum Na levels on post-LT outcomes. We identified 19,537 patients from 2003 to 2010 for whom serum Na levels immediately before LT were available. The patients were divided into 3 groups [hyponatremic (Na ≤ 130 mEq/L), normonatremic (Na = 131-145 mEq/L), and hypernatremic (Na > 145 mEq/L)], and their post-LT outcomes were compared. There was no difference in in-hospital mortality or 90-day survival between patients with hyponatremia and patients with normonatremia. A fraction of the patients (2.4%) had hypernatremia, which was associated with increased in-hospital mortality (11.2% versus 4.2%, P < 0.001) and diminished 90-day survival (86.4% versus 94.0.%, P < 0.001). After adjustments for important clinical variables, the association of pre-LT hypernatremia with posttransplant mortality remained significant with a hazard ratio of 1.13 for each unit increase in the Na level > 145 mEq/L (P < 0.001). The duration of the hospitalization after LT was significantly longer for hypernatremic patients (P < 0.001). In conclusion, hyponatremia per se does not affect post-LT survival. Pre-LT hypernatremia is a highly significant risk factor for post-LT mortality., (© 2014 American Association for the Study of Liver Diseases.)
- Published
- 2014
- Full Text
- View/download PDF
45. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
- Author
-
Congly SE and Leise MD
- Subjects
- Female, Humans, Male, Gastrointestinal Agents therapeutic use, Hepatic Encephalopathy drug therapy, Lactulose therapeutic use, Rifamycins therapeutic use
- Published
- 2014
- Full Text
- View/download PDF
46. Embolization of spontaneous portosystemic shunts for management of severe persistent hepatic encephalopathy.
- Author
-
Singh S, Kamath PS, Andrews JC, and Leise MD
- Subjects
- Female, Humans, Male, Embolization, Therapeutic, Hepatic Encephalopathy therapy
- Published
- 2014
- Full Text
- View/download PDF
47. Management of hepatic encephalopathy in the hospital.
- Author
-
Leise MD, Poterucha JJ, Kamath PS, and Kim WR
- Subjects
- Disease Management, Drug Therapy, Combination, Humans, Inpatients, Lactulose therapeutic use, Metronidazole therapeutic use, Neomycin therapeutic use, Protein Synthesis Inhibitors therapeutic use, Recurrence, Rifamycins therapeutic use, Rifaximin, Terminology as Topic, Gastrointestinal Agents therapeutic use, Hepatic Encephalopathy drug therapy
- Abstract
Hepatic encephalopathy (HE) develops in up to 50% of patients with cirrhosis and is a feature of decompensated cirrhosis. With the goal of reviewing the evidence for treatment and prevention of overt hepatic encephalopathy, pubmed was searched using search terms hepatic encephalopathy AND treatment, limited to human studies from January 1, 2003, through December 1, 2013, and supplemented by key references. The inpatient incidence of HE is approximately 23,000 annually, and management of these patients is common for internists and subspecialists. Treatment of the hospitalized patient with HE has changed in recent years. Treatment entails 2 phases: induction and maintenance of remission. Most cases of significant HE are precipitated by infection, gastrointestinal bleeding, medications, or other culprits. All patients should be evaluated for secondary triggers of HE, and treatment should be initiated with a nonabsorbable disaccharide (ie, lactulose) in most patients. Rifaximin (off label) can be added in patients not responding to lactulose. Neomycin is a less preferred alternative to rifaximin owing to its adverse effect profile. Other therapies, including zinc, L-ornithine-L-aspartate, and branched-chain amino acids, can be considered for patients not responding to disaccharides and nonabsorbable antibiotics. Large portosystemic shunts may be embolized in patients with medically refractory recurrent or severe HE with otherwise well-compensated cirrhosis. Molecular Adsorbent Recirculating System is now available for patients with severe HE who do not respond to medical therapy. It is critically important that patients hospitalized with significant HE continue maintenance therapy at the time of dismissal to prevent further episodes. Patients with a first-time episode of HE can be administered lactulose, and careful instructions should be provided to patients and caregivers about dose titration to achieve 3 bowel movements daily. Patients with recurrent HE episodes despite lactulose use benefit from the addition of rifaximin, which decreases the frequency of recurrent HE episodes and related hospitalizations. Last, patients and their families should be counseled about the risk of motor vehicle accidents, which require mandatory reporting to the Department of Motor Vehicles in some states., (Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
48. Endoscopic ultrasound-guided portal-systemic pressure gradient measurement.
- Author
-
Fujii-Lau LL, Leise MD, Kamath PS, Gleeson FC, and Levy MJ
- Subjects
- Adult, Esophageal and Gastric Varices diagnostic imaging, Gastrointestinal Hemorrhage diagnostic imaging, Humans, Hypertension, Portal complications, Male, Noonan Syndrome complications, Radiography, Endosonography, Esophageal and Gastric Varices etiology, Gastrointestinal Hemorrhage etiology, Hypertension, Portal diagnostic imaging, Portal Pressure
- Published
- 2014
- Full Text
- View/download PDF
49. Drug-induced liver injury.
- Author
-
Leise MD, Poterucha JJ, and Talwalkar JA
- Subjects
- Adult, Causality, China epidemiology, Comorbidity, Democratic People's Republic of Korea epidemiology, Dietary Supplements adverse effects, Enzyme Inhibitors adverse effects, Female, Fluoroquinolones adverse effects, France epidemiology, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Iceland epidemiology, Male, Protein-Tyrosine Kinases metabolism, Republic of Korea epidemiology, Spain epidemiology, Tumor Necrosis Factor-alpha adverse effects, United States epidemiology, Amoxicillin adverse effects, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Chemical and Drug Induced Liver Injury epidemiology, Clavulanic Acid adverse effects, Isoniazid adverse effects, Liver Diseases epidemiology
- Abstract
Drug hepatoxicity can be nonidiosyncratic (predictable), as in the case of acetaminophen, or idiosyncratic (unpredictable). This review article focuses primarily on idiosyncratic drug-induced liver injury (DILI). New epidemiologic data suggest that approximately 20 new cases of DILI per 100,000 persons occur each year. Idiosyncratic DILI accounts for 11% of the cases of acute liver failure in the United States. Risk factors for DILI include medication dose, drug lipophilicity, and extent of hepatic metabolism. There is mixed evidence to support the role of host factors such as age, sex, and chronic liver disease in the development of DILI. For specific drugs, a genetic predisposition appears to be a risk factor for DILI. Suspected cases of idiosyncratic DILI should be categorized as hepatitic, cholestatic, or mixed on the basis of the degree/ratio of abnormalities in the alanine aminotransferase and alkaline phosphatase. A careful evaluation for other causes of liver disease should be performed, though a liver biopsy is rarely needed. There is evidence that some patients with DILI may actually have hepatitis E and this diagnosis should be considered. Amoxicillin/clavulanate isoniazid, and nonsteroidal anti-inflammatory drugs are among the most common causes of DILI. Drug discontinuation or dechallenge should lead to an improvement in liver biochemistries in most patients, though a bilirubin value of more than 3 g/dL is associated with mortality of at least 10%. New biomarkers for DILI using proteomics and micro RNA appear promising but require further study. New studies on drugs with potential for causing DILI are reviewed herein, including tumor necrosis factor-alpha antagonists, fluoroquinolones, tyrosine kinase inhibitors, statins, and supplements. PubMed was used with search terms of drug induced liver injury OR DILI with filter settings of "English language" and "humans" and custom date range of "January 1, 2000." The authors also manually searched bibliographies from key references and included seminal references before the year 2000., (Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
50. Role of immunosuppression in post-endoscopic retrograde cholangiopancreatography pancreatitis after liver transplantation: a retrospective analysis.
- Author
-
Law R, Leal C, Dayyeh BA, Leise MD, Balderramo D, Baron TH, and Cardenas A
- Subjects
- Acute Disease, Adult, Aged, Chi-Square Distribution, Female, Hospitals, High-Volume, Humans, Logistic Models, Male, Middle Aged, Minnesota, Multivariate Analysis, Odds Ratio, Pancreatitis diagnosis, Pancreatitis etiology, Retrospective Studies, Risk Factors, Spain, Time Factors, Adrenal Cortex Hormones therapeutic use, Cholangiopancreatography, Endoscopic Retrograde adverse effects, Immunosuppressive Agents therapeutic use, Liver Transplantation adverse effects, Pancreatitis prevention & control, Prednisone therapeutic use
- Abstract
Endoscopic retrograde cholangiopancreatography (ERCP) is frequently used for diagnosis and therapeutic interventions in recipients of liver transplantation (LT) who develop biliary complications. Post-endoscopic retrograde cholangiopancreatography acute pancreatitis (PEP) is the most common major adverse event after ERCP; however, the frequency of PEP in LT recipients is not well established. We aimed to determine the rate of PEP in this population and to identify its predictors, especially among immunosuppressive agents. We reviewed all ERCP procedures performed in LT recipients after duct-to-duct biliary anastomoses at 2 high-volume transplant centers. Patients who had undergone sphincterotomy or had a surgically altered pancreaticobiliary anatomy before LT were excluded. Electronic medical records and endoscopy databases were used to obtain clinical, endoscopic, and medication data. A multivariate logistic regression analysis was used to determine predictors of PEP in this cohort. In all, 730 ERCP procedures were performed in 301 patients during the study period with an observed PEP rate of 3% (22/730). A univariate analysis revealed an increased risk of PEP with index ERCP after LT [odds ratio (OR) = 4.04, 95% confidence interval (CI) = 1.40-11.65] and in cases with difficult biliary cannulation (OR = 2.89, 95% CI = 1.10-7.65), whereas prednisone use was found to have a protective effect in both univariate (OR = 0.34, 95% CI = 0.14-0.84) and multivariate analyses (OR = 0.22, 95% CI = 0.09-0.57) after adjustments for difficult biliary cannulation and post-LT index ERCP. This retrospective analysis demonstrates that corticosteroid therapy has a protective role in the development of PEP in LT recipients. Further studies are warranted to confirm our findings., (© 2013 American Association for the Study of Liver Diseases.)
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.